Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

This study found that age is the most significant risk factor for hemorrhagic cystitis after hematopoietic stem-cell transplantation, with additional risk factors including cyclophosphamide-based prophylaxis and, among male recipients, prostatic hyperplasia.

This study found that among men over 70, certain genetic variants associated with skin pigmentation affect serum PSA levels, with implications for how sun sensitivity and exposure may influence prostate cancer risk.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

In this study, androgenetic alopecia patients with thin hair were found to have a higher likelihood of experiencing prostatic enlargement and related urinary symptoms compared to those with thicker hair.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This study found that men with vertex baldness had higher serum dihydrotestosterone levels compared to those with frontal baldness, suggesting different hormonal profiles between these two groups in androgenetic alopecia.

This study identified 193 plasma proteins associated with prostate cancer risk, validating 20 high-risk proteins including KLK3, and pinpointed potential drug targets like HSPB1, RRM2B, and PSCA through genetic analysis, offering new insights for biomarkers and treatments.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

This study observed that women with PCOS from Khyber Pakhtunkhwa had significantly higher serum PSA levels, which positively correlated with hirsutism, testosterone, and DHEAS levels compared to healthy controls.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Human prostate cells produce more WISP1/CCN4 when there's not enough oxygen.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This review discusses the potential link between long-term transdermal exposure to sex hormones from antiperspirants and increased breast and prostate cancer rates, calling for further research to confirm this theory.

This study found that the pH dependency of rat steroid 5α-reductase type II isozyme significantly affects its kinetic properties, including Vmax and Km, suggesting past discrepancies in literature may arise from these pH variances during assays.

Finasteride treats hair loss but may affect prostate cancer detection.

This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This study observed that men with vertex androgenetic alopecia at age 40 had a higher risk of early-onset prostate cancer, suggesting a potential link between the conditions.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.